Cargando…
Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants
Background: Azvudine (FNC) is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). However, drug interactions with azvudine have been poorly studied, especially with no reported cases of azvudine with anticoagulants such as warfarin and rivaroxaban. Case summary: The pat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235595/ https://www.ncbi.nlm.nih.gov/pubmed/37274098 http://dx.doi.org/10.3389/fphar.2023.1191608 |
_version_ | 1785052719522775040 |
---|---|
author | Zhang, Xi Jiao, Fengwei Li, Guangrun Yu, Xiaojia Pei, Yuqing Zhang, Ying Wang, Zihui Li, Pengfei |
author_facet | Zhang, Xi Jiao, Fengwei Li, Guangrun Yu, Xiaojia Pei, Yuqing Zhang, Ying Wang, Zihui Li, Pengfei |
author_sort | Zhang, Xi |
collection | PubMed |
description | Background: Azvudine (FNC) is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). However, drug interactions with azvudine have been poorly studied, especially with no reported cases of azvudine with anticoagulants such as warfarin and rivaroxaban. Case summary: The patient was diagnosed with lower limb venous thrombosis and took warfarin regularly. The international normalized ratio (INR) was stable (2.0–3.0). However, the INR increased to 7.52 after administering azvudine. The patient had no other factors justifying this change. This increase in INR occurred again with the administration of azvudine in combination with rivaroxaban, and the INR increased to 18.91. After azvudine administration was stopped, the INR did not increase when rivaroxaban was used alone. Conclusion: Azvudine, warfarin, and rivaroxaban might have previously unidentified drug interactions that increased the INR. Therefore, the INR must be closely monitored when they are concomitantly administered in COVID-19 patients. |
format | Online Article Text |
id | pubmed-10235595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102355952023-06-03 Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants Zhang, Xi Jiao, Fengwei Li, Guangrun Yu, Xiaojia Pei, Yuqing Zhang, Ying Wang, Zihui Li, Pengfei Front Pharmacol Pharmacology Background: Azvudine (FNC) is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). However, drug interactions with azvudine have been poorly studied, especially with no reported cases of azvudine with anticoagulants such as warfarin and rivaroxaban. Case summary: The patient was diagnosed with lower limb venous thrombosis and took warfarin regularly. The international normalized ratio (INR) was stable (2.0–3.0). However, the INR increased to 7.52 after administering azvudine. The patient had no other factors justifying this change. This increase in INR occurred again with the administration of azvudine in combination with rivaroxaban, and the INR increased to 18.91. After azvudine administration was stopped, the INR did not increase when rivaroxaban was used alone. Conclusion: Azvudine, warfarin, and rivaroxaban might have previously unidentified drug interactions that increased the INR. Therefore, the INR must be closely monitored when they are concomitantly administered in COVID-19 patients. Frontiers Media S.A. 2023-05-19 /pmc/articles/PMC10235595/ /pubmed/37274098 http://dx.doi.org/10.3389/fphar.2023.1191608 Text en Copyright © 2023 Zhang, Jiao, Li, Yu, Pei, Zhang, Wang and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Xi Jiao, Fengwei Li, Guangrun Yu, Xiaojia Pei, Yuqing Zhang, Ying Wang, Zihui Li, Pengfei Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants |
title | Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants |
title_full | Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants |
title_fullStr | Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants |
title_full_unstemmed | Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants |
title_short | Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants |
title_sort | elevated inr in a covid-19 patient after concomitant administration of azvudine and anticoagulants |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235595/ https://www.ncbi.nlm.nih.gov/pubmed/37274098 http://dx.doi.org/10.3389/fphar.2023.1191608 |
work_keys_str_mv | AT zhangxi elevatedinrinacovid19patientafterconcomitantadministrationofazvudineandanticoagulants AT jiaofengwei elevatedinrinacovid19patientafterconcomitantadministrationofazvudineandanticoagulants AT liguangrun elevatedinrinacovid19patientafterconcomitantadministrationofazvudineandanticoagulants AT yuxiaojia elevatedinrinacovid19patientafterconcomitantadministrationofazvudineandanticoagulants AT peiyuqing elevatedinrinacovid19patientafterconcomitantadministrationofazvudineandanticoagulants AT zhangying elevatedinrinacovid19patientafterconcomitantadministrationofazvudineandanticoagulants AT wangzihui elevatedinrinacovid19patientafterconcomitantadministrationofazvudineandanticoagulants AT lipengfei elevatedinrinacovid19patientafterconcomitantadministrationofazvudineandanticoagulants |